摘要
药物治疗是宫颈癌综合治疗中除手术和放疗外的另一主要治疗手段,目前主要包括传统细胞毒性化疗、靶向、免疫治疗。近年来关于同步化疗、新辅助化疗、辅助化疗及姑息化疗等细胞毒性药物化疗能否改善患者生存及其合理的剂量强度、密度均得到研究和完善。随着分子生物学和基因组学的研究发展,靶向治疗研究已经取得了突破性的进展,其中抗血管生成、免疫检查点抑制剂等治疗已经在宫颈癌的治疗中显示出效果,这也为宫颈癌的治疗带来了新的希望。
Abstrct: Drug therapy is another main treatment in the comprehensive regimen of cervical cancer besides surgery and radiotherapy. At present,it mainly includes traditional cytotoxic chemotherapy,targeted therapy and immunotherapy. In recent years,whether concurrent chemotherapy,neoadjuvant chemotherapy,adjuvant chemotherapy and palliative chemotherapy can improve the survival of patients and their reasonable dose intensity and density have been studied and improved.With the development of molecular biology and genomics,targeted therapy has made breakthroughs. Antiangiogenesis,immune checkpoint inhibitors therapies have been shown to be effective in the treatment of cervical cancer,which brings new hope for the treatment of cervical cancer.
引文
[1]Siegel RL,Miller KD,Jemal A.Cancer statistics[J].CA Cancer JClin,2016,66:7-30.
[2]Cervical Cancer Stages-American Cancer Society.https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/staged.Accessed21.01.18.
[3]Moore DH,Tian C,Monk BJ,et al.Prognostic factors for response to cisplatin based chemotherapy in advanced cervical carcinoma:A Gynecologic Oneology Group Study[J].Gynecol Oncol,2010,116:44-49.
[4]Thigpen T,Shingleton H,Homesley H,et al.Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix:A phaseⅡstudy of the Gynecologic Oncology Group[J].Cancer,1981,48:899-903.
[5]Moore DH,Blessing JA,Mc Quellon RP,et al.PhaseⅢstudy of cisplatin with or without paclitaxel in Stage IVB,recurrent,or persistent squamous cell carcinoma of the cervix:A Gynecologic Oncology Group Study[J].J Clin Oncol,2004,22:3113-3119.
[6]Monk BJ,Sill MW,Mc Meekin DS,et al.PhaseⅢtrial of four cisplatin-containing doublet combinations in stageⅣB,recurrent,or persistent cervical carcinoma:A Gynecologic Oncology Group study[J].J Clin Oncol,2009,27(28):4649-4655.
[7]Kitagawa R,Katsumata N,Shibata T,et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer:The open-label randomized phaseⅢtrial JCOG0505[J].J Clin Oncol,2015,33(19):2129-2135.
[8]Boussios S,Seraj E,Zarkavelis G,et al.Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens:where do we stand?A literature review[J].Crit Rev Oncol Hematol,2016,108:164-174.
[9]Kumar L,Pramanik R,Kumar S,et al.Neoadjuvant chemotherapy in gynaecological cancers-implications for staging[J].Best Pract Res Clin Obstet Gynaecol,2015,29(6):790-801.
[10]Kumar L,Gupta S.Integrating chemotherapy in the management of cervix cancer-a critical appraisal[J].Oncology,2016,91(suppl):8-12.
[11]Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-Analysis Collaboration.Neoadjuvant chemotherapy for locally advanced cervical cancer:A systematic review and meta-analysis of individual patient data from 21 randomised trials[J].Eur JCancer,2003,39(17):2470-2486.
[12]Loizzi V,Cormio G,Vicino M,et al.Neoadjuvant Chemotherapy:An alternative option of treatment for locally advanced cervical cancer[J].Gynecol Obstet Invest,2008,65(2):96-103.
[13]Kim HS,Sardi JE,Katsumata N,et al.Efficacy of neoadjuvant chemotherapy in patients with FIGO stageⅠB1 toⅡA cervical cancer:An international collaborative meta-analysis[J].Eur JSurg Oncol,2013,39:115-124.
[14]Rydzewska L,Tierney J,Vale CL,et al.Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J/CD].Cochrane Database Syst Rev,2012,12:CD007406.
[15]Katsumata N,Yoshikawa H,Kobayashi H,et al.PhaseⅢrandomized controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stagesⅠB2,ⅡA2,andⅡBcervical cancer:A Japan Clinical Oncology Group trial(JCOG0102)[J].Br J Cancer,2013,108:1957-1963.
[16]Singh RB,Chandra S,M ohanti BK,et al.Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma:A pilot study[J].Gynecol Oncol,2013,129:124-128.
[17]Mc Cormack M,Kadalayil L,Hackshaw A,et al.A phaseⅡstudy of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer[J].Br J Cancer,2013,108(12):2464-2469.
[18]Mc Cormack M.A phaseⅢmulticentre trial of weekly induction chemotherapy followed by standard chemoradiation vs standard chemoradioation alone in patients with locally advanced cervical cancer[EB/OL].(2012-9-27)[2018-18-16].http://www.ctc.ucl.ac.uk/Trial Details.aspx?Trial=89.
[19]Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer:A systematic review and meta-analysis of individual patient data from 18 randomized trials[J].J Clin Oncol,2008,26(35):5802-5812.
[20]Green JA,Kirwan JJ,Tierney J,et al.Concomitant chemotherapy and radiationtherapy for cancer of the uterine cervix[J/CD].Cochrane Database Syst Rev,2005,3:CD002225.
[21]Petrelli F,De Stefani A,Raspagliesi F,et al.Radiotherapy with concurrent cisplatin based doublet or weekly cisplatin for cervical cancer:A systemic review and meta-analysis[J].Gynecol Oncol,2014,134:166-171.
[22]Datta NR,Stutz E,Liu M,et al.Concurrent chemoradiotherapy vs.Radiotherapy alone in locally advanced cervix cancer:Asystematic review and meta-analysis[J].Gynecol Oncol,2017,145(2):374-385.
[23]Gupta S,Maheshwari A,Parab P,et al.Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With StageⅠB2,ⅡA,orⅡB Squamous Cervical Cancer:A Randomized Controlled Trial[J].J Clin Oncol,2018,36(16):1548-1555.
[24]Shrivastava S,Mahantshetty U,Engineer R,et al.Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO StageⅢB Squamous Cell Carcinoma of the Uterin Cervix:A Randomized Clinical Trial[J].JAMA Oncol,2018,4(4):506-513.
[25]Rosa DD,Medeiros LR,Edelweiss MI,et al.Adjuvant platinumbased chemotherapy for early stage cervical cancer[J/CD].Cochrane Database Syst Rev,2012,6:CD005342.
[26]Tzioras S,Pavlidis N,Paraskevaidis E,et al.Effects of different chemotherapy regimens on survival for advanced cervical cancer:Systematic review and meta-analysis[J].Cancer Treat Rev,2007,33:24-38.
[27]Wright AA,Howitt BE,Myers AP,et al.Oncogenic mutations in cervical cancer:Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix[J].Cancer,2013,119:3776-3783.
[28]Ojesina AI,Lichtenstein L,Freeman SS,et al.Landscape of genomic alterations in cervical carcinomas[J].Nature,2014,506:371-375.
[29]Monk BJ,Willmott LJ,Sumner DA.Anti-angiogenesis agents in metastatic or recurrent cervical cancer[J].Gynecol Oncol,2010,116:181-186.
[30]Jain RK.Normalization of tumor vaseulature:An emerging concept in anti-angiogenesis therapy[J].Science,2005,307(5706):58-62.
[31]Monk BJ,Sill MW,Burger RA,et al.PhaseⅡtrial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix:A gynecologic oncology group study[J].J Clin Oncol,2009,27(7):1069-1074.
[32]Zighelboim I,Wright JD,Gao F,et al.Multicenter phaseⅡtrial of topotecan,cisplatin and bevacizumab for recurrentor persistent cervical cancer[J].Gynecol Oncol,2013,130(1):64-68.
[33]Tewari KS,Sill MW,Long HJ,et al.Improved survival with bevacizumab in advanced cervical cancer[J].N Engl J Med,2014,370(8):734-743.
[34]Tewari KS,Sill MW,Penson RT,et al.Bevacizumab for advanced cervical cancer:Final overall survival and adverse event analysis of a randomised,controlled,open-label,phase 3 trial(Gynecologic Oncology Group 240)[J].Lancet,2017,390(10103):1654-1663.
[35]Woodworth CD,Diefendorf LP,Jette DF,et al.Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavims type 16[J].Virology,2011,421(1):19-27.
[36]Zagouri F,Sergentanis TN,Chrysikos D,et al.Molecularly targeted therapies in cervical cancer.A systematic review[J].Gynecol Oncol,2012,126(2):291-303.
[37]Kurtz JE,Hardy-Bessard AC,Deslandres M,et al.Cetuximab,topotecan and cisplatin for the treatment of advanced cervical cancer:A phaseⅡGINECO trial[J].Gynecol Oncol,2009,113(1):16-20.
[38]Nogueira-Rodrigues A,Moralez G,Grazziotin R,et al.PhaseⅡtrial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer[J].Cancer,2014,120(8):1187-1193.
[39]Eskander RN,Tewari KS.Beyond angiogenesis blockade:Targeted therapy for advanced cervical cancer[J].J Gynecol Oncol,2014,25:249-259.
[40]Monk BJ,Mas Lopez L,Zarba JJ,et al.PhaseⅡ,open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer[J].J Clin Oncol,2010,28(22):3562-3569.
[41]Dong H,Strome SE,Salomao DR,et al.Tumor-associated B7-H1promotes T-cell apoptosis:A potential mechanism of immune evasion[J].Nat Med,2002,8(8):793-800.
[42]Mezache L,Paniccia B,Nyinawabera A,et al.Enhanced expression of PD-L1 in cervical intraepithelial neoplasia and cervical cancers[J].Mod Pathol,2015,28:1594-1602.
[43]Heeren AM,de Boer E,Bleeker MC,et al.Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area[J].Oncotarget,2015,6:32484-32493.
[44]Frenel SL,Le Tourneau C,O'Neil BH,et al.Pembrolizumab in patients with advanced cervical squamous cell cancer:Preliminary results from the phase Ib KEYNOTE-028 study[J].J Clin Oncol,2016,34:abstr5515.
